If you have been reading about HGF mimetic and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-20. Where a claim depends on a specific study, the study is described rather than over-claimed.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
== Wagyu beef grades == Beef grades indicate the meat quality, and in Japan they are determined based on the "Beef Carcass Trade Standards" approved by the Ministry of Agriculture, Forestry and Fisheries. Two factors are used to determine the rating: the yield grade and the meat quality grade. The yield grade has three levels: A, B, and C, with A being the highest. The meat quality grade has five levels: 5, 4, 3, 2, and 1, with 5 being the highest. Beef is graded in 15 combinations: A1 to A5, B1 to B5, and C1 to C5, with A5 representing the highest quality for both yield and meat quality. The yield grade refers to the percentage of edible meat in the carcass. The meat quality grade is determined by four criteria: marbling, meat color, firmness and texture, and fat luster and quality.
A follow-up analysis, and a letter to the editor by Gregory Francis from the Department of Psychological Sciences, Purdue University, demonstrated that the problem in the paper could be a simple reporting error in which t-statistics were reported as F-statistics by mistake. Francis also showed that this error does not negate the findings in the original article. In November 2022, the Israeli TV investigative show Hamakor (Channel 13), aired an episode questioning a number of Ariely's studies that were not reproducible or whose reliability was dubious in terms of the way they were carried out, the data collected, or whether the studies were carried out at all. For example, Ariely claimed that data for his "Ten Commandments" study were collected in 2004–2005 at UCLA with the assistance of Aimee Drolet Rossi. However, despite being thanked in the 2004 paper for collecting the data almost 20 years later, Rossi denies having run the study, and UCLA has issued a statement that the study did not take place there. Ariely told The New Yorker that the surveys were collected at UCLA but processed by an assistant at MIT, a mixup that he credited for the confusion surrounding Rossi and UCLA's role in the study. An analysis conducted by the American Marketing Association on the study in question found that the study's results were largely replicable using the data provided by the authors, although conditions had been dropped from the first two experiments in the study.
== Pathology == Saccharopinuria (high amounts of saccharopine in the urine) and saccharopinemia (an excess of saccharopine in the blood) are conditions present in some inherited disorders of lysine degradation.
=== July to December 2003 === American forces detained the family of an unidentified lieutenant general to induce him to turn himself in. The abuses at Abu Ghraib prison were reportedly committed by MPs. There are allegations that private contractors contributed to them as well and that intelligence agencies such as the CIA ordered them to do so in order to break prisoners for interrogations. It is said to be a usual practice in other US prisons as well, such as in Afghanistan and Guantanamo Bay. The International Committee of the Red Cross submitted a detailed report to the U.S. Army in October 2003 about abuses in prisons, and the president of the Red Cross stated he had informed high-ranking members of the Bush administration about the abuses during a meeting in the White House in January 2004. A soldier came forward that month with photos of abuse that he found disturbing, some showed the stacking of prisoners into a human pyramid, with one prisoner's skin visibly bearing a slur written in English. Another showed a prisoner being forced to stand on a box with wires attached to his head and hands, who had reportedly been told that if he fell off the box, he would be electrocuted. Photos released to the public later included a person being attacked by a guard dog, which the soldier involved described as being useful for intimidation of prisoners. It was also reported that an Iraqi hired as a translator raped a juvenile male prisoner while a female soldier took pictures.
Sources: en.wikipedia.org
=== Bhumjaithai Party === Incumbent prime minister Anutin Charnvirakul declared victory following the elections. While acknowledging that the official number of MPs have not yet been certified, Anutin stated that the party accepted the expectations from voters that Bhumjaithai would help form the next government. He also promised to govern with integrity, uphold democracy, and congratulated MPs from all parties who won their seats. When asked which coalition Bhumjaithai would make, Anutin stated that he would hold a meeting with the party's executive committee and wait for figures to stabilise.
Radioactive waste comes from a number of sources. In countries with nuclear power plants, nuclear armament, or nuclear fuel treatment plants, the majority of waste originates from the nuclear fuel cycle and nuclear weapons reprocessing. Other sources include medical and industrial wastes, as well as naturally occurring radioactive materials (NORM) that can be concentrated as a result of the processing or consumption of coal, oil, and gas, and some minerals, as discussed below.
== Mechanism of action == GLP-1 poly-agonist peptides work by activating two hormone receptors rather than one. The two receptors targeted are both triggered naturally after eating, but they act on different parts of the body and play complementary roles in regulating blood sugar, appetite, and fat metabolism. In the pancreas, both receptors stimulate insulin release in response to elevated blood glucose, but through slightly different cellular pathways. Activating both at once produces a stronger insulin response than either receptor alone. The two receptors also balance each other in their effects on glucagon; GIP raises glucagon when blood sugar is too low, while GLP-1 suppresses glucagon when blood sugar is too high. In fat tissue, GIP promotes the removal of triglycerides from the bloodstream, while GLP-1 encourages fat breakdown through signals sent via the central nervous system. Both hormones also reduce fat build up in the liver and lower insulin resistance.
Sources: en.wikipedia.org
Surface bodies of water provide environments that dry out and rewet. Wet-dry cycles concentrate prebiotic compounds and enable condensation reactions to polymerise macromolecules. Moreover, lakes and ponds receive detrital input from weathering of continental apatite-containing rocks, the most common source of phosphates. The amount of exposed continental crust in the Hadean is unknown, but models of early ocean depths and rates of ocean island and continental crust growth make it plausible that there was exposed land. Another line of evidence for a surface start to life is the requirement for Ultraviolet radiation (UV) for organism function. UV is necessary for the formation of the U+C nucleotide base pair by partial hydrolysis and nucleobase loss. Simultaneously, UV can be harmful and sterilising to life, especially for simple early lifeforms with little ability to repair radiation damage. Radiation levels from a young Sun were likely greater, and, with no ozone layer, harmful shortwave UV rays would reach the surface of Earth. For life to begin, a shielded environment with influx from UV-exposed sources is necessary to both benefit and protect from UV. Shielding under ice, liquid water, mineral surfaces (e.g. clay) or regolith is possible in a range of surface water settings.
=== Other conditions === Previous hand injury Ledderhose disease (plantar fibromatosis) Epilepsy (possibly due to anti-convulsive medication) Higher-than-average fasting blood glucose level Diabetes mellitus HIV Macrophallism Previous myocardial infarction
==== Antipseudomonal antibiotics ==== The Gram-negative species, Pseudomonas aeruginosa, is naturally resistant to many antibiotic classes. There were many efforts in the 1960s and 1970s to develop antibiotics that are active against Pseudomonas species. There are two chemical classes within the group: carboxypenicillins and ureidopenicillins. All are given by injection: none can be given by mouth.
Two preparations of botulinum antitoxins are available for treatment of botulism. Trivalent (serotypes A, B, E) botulinum antitoxin is derived from equine sources using whole antibodies. The second antitoxin is heptavalent botulinum antitoxin (serotypes A, B, C, D, E, F, G), which is derived from equine antibodies that have been altered to make them less immunogenic. This antitoxin is effective against all main strains of botulism.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.